Premium
Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease
Author(s) -
Yarchoan Robert,
Thomas Rose V.,
Grafman Jordan,
Wichman Alison,
Dalakas Marinos,
McAtee Nanette,
Berg Gary,
Fischl Margaret,
Perno Carlo Federico,
Klecker Raymond W.,
Buchbinder Aby,
Tay Steven,
Larson Steven M.,
Myers Charles E.,
Broder Samuel
Publication year - 1988
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410230722
Subject(s) - administration (probate law) , medicine , term (time) , disease , chemotherapy , pediatrics , surgery , political science , physics , quantum mechanics , law
3′‐Azido‐2′,3′‐dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T‐10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus–associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.